Product/Composition:- | Nalbuphine Injection |
---|---|
Strength:- | 10 mg/mL, 20 mg/mL |
Form:- | Injectable (IM, IV) |
Reference Brands:- | Nalbuphine(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Nalbuphine injectable activates kappa-opioid receptors and blocks mu-opioid receptors, providing analgesia with a ceiling effect on respiratory depression. It effectively relieves moderate to severe pain, offering rapid onset, fewer respiratory risks, and suitability for opioid-sensitive patients, making it a safer option for hospital and clinical pain management.
Nalbuphine injectable is approved in the US and EU for managing moderate to severe pain, particularly in hospitals. In the US, brands like Nalbuphine Hydrochloride are regulated by the FDA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the EU, approval by EMA requires comprehensive dossiers, clinical data, and pharmacovigilance plans. Due to its ceiling effect on respiratory depression, nalbuphine is favored for safe analgesia in clinical settings. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for nalbuphine injections, ensuring adherence to European and US standards for safe, effective pain management.